v3.26.1
Cover - shares
6 Months Ended
Jun. 30, 2026
Aug. 11, 2026
Cover [Abstract]    
Entity Registrant Name ARTELO BIOSCIENCES, INC.  
Entity Central Index Key 0001621221  
Document Type 10-Q/A  
Amendment Flag true  
Current Fiscal Year End Date --12-31  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Current Reporting Status Yes  
Document Period End Date Jun. 30, 2026  
Entity Filer Category Non-accelerated Filer  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2026  
Entity Common Stock Shares Outstanding   4,595,068
Entity File Number 001-38951  
Entity Incorporation State Country Code NV  
Entity Tax Identification Number 33-1220924  
Entity Address Address Line 1 505 Lomas Santa Fe  
Entity Address Address Line 2 Suite 160  
Entity Address City Or Town Solana Beach  
Entity Address State Or Province CA  
Entity Address Postal Zip Code 92075  
City Area Code 858  
Local Phone Number 925-7049  
Security 12b Title Common Stock, $0.001 par value per share  
Trading Symbol ARTL  
Security Exchange Name NASDAQ  
Entity Address Country US  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Description The purpose of this Amendment No. 1 (this “Amendment”) to the Quarterly Report on Form 10-Q of Artelo Biosciences, Inc. (the “Company”) for the period ended June 30, 2026 (the “Original Report”), as filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2026, is solely to amend Part II “Item 1. Legal Proceedings” to include information regarding an arbitration claim that was inadvertently omitted from the Original Report. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications of our principal executive officer and principal financial officer are filed as exhibits to this Amendment under Part II “Item 6. Exhibits”. Except as described above, this Amendment makes no other changes to the Original Report. This Amendment does not reflect subsequent events occurring after the original filing of the Original Report or modify or update in any way those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Report and our other filings with the SEC.